Obesity Tx End-Around With Skye Bioscience's Punit Dhillon

Business Of Biotech

We love to hear from our listeners. Send us a message.

While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant last month, Skye Bioscience Chairman and CEO Punit Dhillon is shaking it off. He's confident that his company's antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On this episode of the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics and going deep with Dhillon on why Skye's blood/brain barrier-obeying antibody might turn the GLP-1 and small molecule approaches to obesity on their ears. Over the course of the conversation, we explore the ins-and-outs of the business of metabolic health, a space that's churning out one blockbuster after another.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. Obesity Tx End-Around With Skye Bioscience's Punit Dhillon (00:00:00)

2. Metabolic Health and Biotech Innovations (00:00:04)

3. Biotech Leadership and Strategic Hiring (00:04:43)

4. Challenging the Status Quo in Biotech (00:17:49)

5. Innovative Approaches to Weight Loss (00:26:40)

6. Developing CB1 Inhibition for Weight Loss (00:32:50)

7. Innovative Approach to Obesity Treatment (00:42:58)

8. Balance Between Fitness and Pharmacotherapy (00:56:08)